



6/18-04

J Fan

Please type a plus sign (+) inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/684,151
		Filing Date	October 10, 2003
		First Named Inventor	Segall, Paul E.
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	5	Attorney Docket Number	BIOT-005CON
ENCLOSURES (check all that apply)			
☐ Fee Transmittal Form	☐ Assignment Papers (for an Application)	☐ After Allowance Communication to Group	
☐ Fee Attached	☐ Drawing(s)	☐ Appeal Communication to Board of Appeals and Interferences	
☐ Amendment / Reply	☐ Licensing-related Papers	☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
☐ After Final	☐ Petition	☐ Proprietary Information	
☐ Affidavits/declaration(s)	☐ Petition to Convert to a Provisional Application	☐ Status Letter	
☐ Extension of Time Request	☐ Power of Attorney, Revocation Change of Correspondence Address	☒ Other Enclosure(s) (please identify below):	
☐ Express Abandonment Request	☐ Terminal Disclaimer	Postcard	
☒ Information Disclosure Statement PTO/SB/08a	☐ Request for Refund		
☐ Certified Copy of Priority Documents	☐ CD, Number of CD(s)		
☐ Response to Missing Parts/ Incomplete Application	Remarks		
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	SUSAN C. TALL, 52,272 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	June 16, 2004		

EXPRESS MAIL LABEL NO. 333997437 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**EXPRESS MAIL LABEL NO. 333997437 US**

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Non Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	BIOT-005CON
	First Named Inventor	Segall, Paul E.
	Application Number	10/684,151
	Confirmation No.	2308
	Filing Date	October 10, 2003
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Title:	"PHYSIOLOGICALLY ACCEPTABLE AQUEOUS SOLUTIONS AND METHODS FOR THEIR USE"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


All of the references identified herein were disclosed in parent application serial number 09/530,006, filed 4/20/2000 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.


As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. BIOT-005CON may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 6/16/04

By: 
Susan C. Tall
Registration No. 52,272

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/684,151	
			Filing Date	October 10, 2003	
			First Named Inventor	Segall, Paul E.	
			Art Unit	Not Yet Assigned	
Sheet	1	of	3	Examiner Name	Not Yet Assigned
				Attorney Docket Number	BIOT-005CON

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No.¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code² (if known)				
		US- RE34077		09/1992	Segall et al.	
		US-3,937,821		02/1976	Irikura et al.	
		US- 4,001,401		01/1977	Bonsen et al.	
		US- 4,061,736		12/1977	Morris et al.	
		US- 4,216,205		08/1980	Radiwitz	
		US- 4,649,050		03/1987	Veech	
		US- 4,606,912		08/1986	Rudy et al.	
		US- 4,663,166		05/1987	Veech	
		US- 4,812,310		03/1989	Sato et al.	
		US- 4,879,283		11/1989	Belzer et al	
		US- 4,923,442		05/08/1990	Segall et al.	
		US- 4,927,806		05/1990	Kramer et al.	
		US-4,980,350		03/1990	Kramer et al.	
		US- 5,084,377		01/1992	Rowan et al.	
		US- 5,082,831		01/1192	Leaf et al.	
		US- 5,120,719		06/1992	Iwamoto et al.	
		US- 5,130,230		07/14/1992	Segall et al.	
		US- 5,171,526		12/1992	Wong et al.	
		US- 5,200,398		04/1993	Strasberg et al.	
		US- 5,210,835		05/11/1993	Pfirman	
		US- 5,274,001		12/28/1993	Borody	
		US- 5,306,711		04/1994	Southard	
		US- 5,374,624		12/1994	Segal	
		US- 5,407,428		04/1995	Segal et al.	
		US- 5,407,793		04/1995	Del Nido et al.	
		US- 5,571,801		11/5/1996	Segall et al.	
		US- 5,696,152		12/1997	Southard	
		US- 6,080,538		06/2000	Segall et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known			
			Application Number		10/684,151	
			Filing Date		October 10, 2003	
			First Named Inventor		Segall, Paul E.	
			Group Art Unit		1614	
Sheet	2	of	3	Examiner Name		
				Attorney Docket Number		BIOT-005CON
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO89/10746	11/1989	PCT		
		EP 437,274A	07/1991	EPO		
		WO92/18136	10/1992	PCT		
		WO94/28950	12/1994	PCT		
		WO96/19918	07/1996	PCT		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		(1987). "6% Dextran 70 in 5% Dextrose injection or 0.9% Sodium Chloride injection" 06-3874-R8-Rev. Abbot Laboratories, North Chicago, IL 60064, US	
		(1992). "Media Formulas" ATCC Catalogue of Bacteria & Bacteriophages, pg. 486	
		ALTURA et al., "CA2+ coupling in vascular smooth muscle: Mg2+ and buffer effects on contractility and membrane Ca2+ movements", Canadian Journal of Physiology and Pharm., 1982, 60(4) (459-482), abst.	
		BAILES et al. (1990), "The use of Ultra-profound Hypothermia in a totally exsanguinated and Blood-Substituted canine model, I," Cyrobiology, V. 27: 622-623	
		BELZER et al. (1985). "Combination perfusion-cold storage for optimum cadaver kidney function and utilization" Transplantation, V. 39(2): 118-121	
		BISHOP et al. (1978). "Evaluation of hypertonic citrate flushing solution for kidney preservation using the isolated perfused rat kidney" Transplantation, V. 25(5): 235-239	
		COLLINS (1977). Hypothermic kidney storage" Transplantation Proceedings, V. 9(3): 1529-1534.	
		FISCHER et al. (1985). "Flush solution 2, a new concept for one to three day hypothermic renal storage preservation" Transplantation, V. 39(2): 122-126	
		HULL et al. "Effect of HEPES buffer on corneal storage in MK medium", ACTA OPHTHALMOLOGICA, 1984, 62(6) 900-10, abst.	
		KALLERHOFF et al. (1985). "Effects of preservation conditions and temperature on tissue acidification in canine kidneys" Transplantation, V. 39(5): 485-489.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/684,151
				Filing Date	October 10, 2003
				First Named Inventor	Segall, Paul E.
				Art Unit	
Examiner Name					
Sheet	3	of	3	Attorney Docket Number	BIOT-005CON

		LEAVITT et al. (1990) "Survival from prolonged cardiac arrest in totally exsanguinated hypothermic dogs" FASB J., V. 4(4): A 983.	
		LEHNINGER (1975). Biochemistry, 2 nd Edition, page 829ff.	
		LEPE-ZUNIGA et al., "Toxicity of Light-Exposed HEPES Media", J Immunol Methods 103, 145 (1987)	
		MESSMER, "Characteristics, Effects, and Side Effects of Plasma Substitutes," Bodensee Symposium on Microcirculation (Hammersen and Messmer. Eds) Karger, N.Y., Ch.2 pages 51-70.	
		ROSENBERG (1969). "Perspectives on the Problem of Blood Substitutes". Proc. 12 th Congr. Int. Soc. Blood Transf. No.3 Pt .II pages 737-745	
		ROSS et al., "72 hr Canine Kidney Preservation Without Continuous Perfusion" Transplantation (1976), B.21 (6): 498-501	
		SEGALL et al., (1991). "Animal Models In Ice Cold Bloodless Medicine" FASB J., V.5 (4): A396	
		SMITH (1956), "Studies on Golden Hamsters During Cooling to and Rewarming from Body Temperatures Below 0°C," Proc. Royal Soc. Vol. 145: 391-442.	
		SPAHN (1994). "Cardiovascular and Coronary Physiology of Acute Isovolemic Hemodilution: A review of Nonoxygen-Carrying and Oxygen-Carrying Solutions". Anesth. Analg. V. 78:1000-1021	
		STERNBERG et al., (1990). "Interventive Gerontology, Cloning and Cyronics" Biomedical Advances In Aging. Plenum Press. Ch. 19 pp. 207-219	
		WAGNER et al. (1993). "Pharmacologic and Clinical Considerations In Selecting Crystalloid, Colloidal and Oxygen-Carrying Resuscitation Fluids, Part 1" Clin. Pharm. V. 12: 335-347	
		WAITZ et al. (1991). "Hamsters Live After Hours of Bloodless Hyperbaric O ₂ " FASB J., V. 5(5); 4375	
		WIEDEBERG et al. "Anemic Necrosis of the Liver After Umbilical Vein Catherization", Helvetica Paediatrica Acta, (1979), 34(a) 53-62, abstract	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2